84 related articles for article (PubMed ID: 15499225)
1. Atorvastatin and simvastatin decrease the uptake of acetylated low-density lipoprotein by human monocytes.
Tavridou A; Manolopoulos VG
Pharmacology; 2005 Feb; 73(2):102-5. PubMed ID: 15499225
[TBL] [Abstract][Full Text] [Related]
2. HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.
Teupser D; Bruegel M; Stein O; Stein Y; Thiery J
Biochem Biophys Res Commun; 2001 Dec; 289(4):838-44. PubMed ID: 11735122
[TBL] [Abstract][Full Text] [Related]
3. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
Conde K; Pineda G; Newton RS; Fernandez ML
Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
[TBL] [Abstract][Full Text] [Related]
4. Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol.
Aronow HD; Hess G; Hill J; Kuznik A; Liu LZ
Am J Ther; 2010; 17(2):167-75. PubMed ID: 19770794
[TBL] [Abstract][Full Text] [Related]
5. Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors.
Rodríguez C; Alcudia JF; Martínez-González J; Guadall A; Raposo B; Sánchez-Gómez S; Badimon L
Cardiovasc Res; 2009 Aug; 83(3):595-603. PubMed ID: 19406911
[TBL] [Abstract][Full Text] [Related]
6. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.
Hernández-Perera O; Pérez-Sala D; Navarro-Antolín J; Sánchez-Pascuala R; Hernández G; Díaz C; Lamas S
J Clin Invest; 1998 Jun; 101(12):2711-9. PubMed ID: 9637705
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression.
Moon JH; Kang SB; Park JS; Lee BW; Kang ES; Ahn CW; Lee HC; Cha BS
Metabolism; 2011 Jul; 60(7):930-40. PubMed ID: 20951395
[TBL] [Abstract][Full Text] [Related]
8. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1.
Li D; Chen H; Romeo F; Sawamura T; Saldeen T; Mehta JL
J Pharmacol Exp Ther; 2002 Aug; 302(2):601-5. PubMed ID: 12130721
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of LOX-1 by statins may relate to upregulation of eNOS.
Mehta JL; Li DY; Chen HJ; Joseph J; Romeo F
Biochem Biophys Res Commun; 2001 Dec; 289(4):857-61. PubMed ID: 11735125
[TBL] [Abstract][Full Text] [Related]
10. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells.
Ortego M; Hernández AG; Bustos C; Blanco-Colio LM; Hernández-Presa MA; Tuñón J; Egido J
Eur J Pharmacol; 2002 Jul; 448(2-3):113-21. PubMed ID: 12144930
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes.
Fuhrman B; Koren L; Volkova N; Keidar S; Hayek T; Aviram M
Atherosclerosis; 2002 Sep; 164(1):179-85. PubMed ID: 12119208
[TBL] [Abstract][Full Text] [Related]
12. Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes.
Ichida Y; Hasegawa G; Fukui M; Obayashi H; Ohta M; Fujinami A; Ohta K; Nakano K; Yoshikawa T; Nakamura N
Pharmacology; 2006; 76(1):34-9. PubMed ID: 16227702
[TBL] [Abstract][Full Text] [Related]
13. Effects of atorvastatin and simvastatin on atrial plateau currents.
Vaquero M; Caballero R; Gómez R; Núñez L; Tamargo J; Delpón E
J Mol Cell Cardiol; 2007 May; 42(5):931-45. PubMed ID: 17466325
[TBL] [Abstract][Full Text] [Related]
14. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells.
Sadaria MR; Reppert AE; Yu JA; Meng X; Fullerton DA; Reece TB; Weyant MJ
J Thorac Cardiovasc Surg; 2011 Nov; 142(5):1152-60. PubMed ID: 22014341
[TBL] [Abstract][Full Text] [Related]
15. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Morikawa S; Umetani M; Nakagawa S; Yamazaki H; Suganami H; Inoue K; Kitahara M; Hamakubo T; Kodama T; Saito Y
J Atheroscler Thromb; 2000; 7(3):138-44. PubMed ID: 11480454
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
Wilcox LJ; Barrett PH; Huff MW
J Lipid Res; 1999 Jun; 40(6):1078-89. PubMed ID: 10357840
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
Broncel M; Bała A; Koter-Michalak M; Duchnowicz P; Wojsznis W; Chojnowska-Jezierska J
Wiad Lek; 2007; 60(7-8):321-8. PubMed ID: 18175550
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures.
Ruiz-Gaspa S; Nogues X; Enjuanes A; Monllau JC; Blanch J; Carreras R; Mellibovsky L; Grinberg D; Balcells S; Díez-Perez A; Pedro-Botet J
J Cell Biochem; 2007 Aug; 101(6):1430-8. PubMed ID: 17252541
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of statins in atherosclerosis and diabetes.
Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
Stern RH; Yang BB; Hounslow NJ; MacMahon M; Abel RB; Olson SC
J Clin Pharmacol; 2000 Jun; 40(6):616-23. PubMed ID: 10868312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
